澳股詳情

本頁面由Tiger Trade Technology Pte. Ltd.提供服務

PERCHERON FPO

0.004

0.000-11.11%

成交量：3,272

成交額：13

市值：728.97萬

市盈率：-0.98

高：0.004

開：0.004

低：0.004

收：0.005

52周最高：0.011

52周最低：0.002

股本：18.22億

流通股本：8.17億

量比：0.15

換手率：0.00%

股息：- -

股息率：- -

每股收益(TTM):-0.004

每股收益(LYR):-0.004

淨資產收益率：-54.66%

總資產收益率：-28.90%

市淨率：0.97

市盈率(LYR):-0.98

資料載入中...

總覽公司新聞資訊公告

概念

no data

沒有相關數據

資金流向

資金流入：

資金流出：

新聞資訊

Percheron Therapeutics尋求停牌，擬融資以資助與範德比爾特健康的合作研究

Percheron Therapeutics Ltd——範德比爾特健康中心將開展Hmbd-002治療急性髓系白血病的臨床試驗

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"Easy breezy. No more feesies.","description":"Tiger Trade is a mobile trading app offering real time data, low commission fees and a free demo account. Download now to start investing in ETFs, options and the global share market.","keywords":"老虎國際,美股交易,港股交易,交易美股,股票信息,股價,美股行情,美股打新,港股打新,IPO打新,購買美股,全球投資","social":{"ogDescription":"Tiger Trade is a mobile trading app offering real time data, low commission fees and a free demo account. Download now to start investing in ETFs, options and the global share market.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.thetigerbrokers.com/hant/stock/PER.AU"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"NZL","license":"TBKIWI","edition":"fundamental","symbol":"PER.AU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"PER.AU\",,,,,undefined,":{"symbol":"PER.AU","market":"AU","secType":"STK","nameCN":"PERCHERON FPO","latestPrice":0.004,"timestamp":1789521654074,"preClose":0.0045,"halted":0,"volume":3272,"delay":0,"changeRate":-0.11111111111111102,"nameEN":"PERCHERON FPO","floatShares":816628906,"shares":1822415536,"eps":-0.0041,"marketStatus":"交易中","change":-0.0005,"latestTime":"09-16 11:46:37 AEST","open":0.004,"high":0.004,"low":0.004,"amount":13,"amplitude":0,"askPrice":0.005,"askSize":6211461,"bidPrice":0.004,"bidSize":21345831,"shortable":3,"etf":0,"ttmEps":-0.0041,"tradingStatus":2,"nextMarketStatus":{"tag":"收盤","tradingStatus":0,"beginTime":1789538400000},"marketStatusCode":2,"adr":0,"exchange":"ASX","adjPreClose":0.0045,"openAndCloseTimeList":[[1789516800000,1789538400000]],"volumeRatio":0.146795,"lotSize":1,"tradeCurrency":"AUD","auctionPricing":{"symbol":"PER.AU","preClose":0.004,"auctionPrice":0.004,"auctionVolume":3272,"auctionTime":1789513371102,"referenceTime":1788863403091,"auction":1,"marketStatus":"盘前竞价","timestamp":1789513371102}},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"PER.AU\",,,,,undefined,":{"symbol":"PER.AU","floatShares":816628906,"roa":"-28.90%","roe":"-54.66%","lyrEps":-0.0041,"volumeRatio":0.146795,"shares":1822415536,"dividePrice":0,"high":0.004,"amplitude":0,"preClose":0.0045,"low":0.004,"week52Low":0.002,"pbRate":"0.97","psRate":"8.64","week52High":0.011,"institutionHeld":0,"latestPrice":0.004,"committee":0.549197,"eps":-0.0041,"divideRate":0,"volume":3272,"delay":0,"ttmEps":-0.0041,"open":0.004,"prevYearClose":0.009,"prevWeekClose":0.004,"prevMonthClose":0.005,"prevQuarterClose":0.003,"fiveDayClose":0.004,"twentyDayClose":0.005,"sixtyDayClose":0.004},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/PER.AU\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"PER.AU\",market:\"AU\",,,undefined,":[],"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"PER.AU\",pageSize:4,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"1139987884","title":"Percheron Therapeutics尋求停牌，擬融資以資助與範德比爾特健康的合作研究","url":"https://stock-news.laohu8.com/highlight/detail?id=1139987884","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1139987884?lang=zh_tw&edition=fundamental","pubTime":"2026-08-28 07:03","pubTimestamp":1787871792,"startTime":"0","endTime":"0","summary":"Percheron Therapeutics宣布，已申请股票交易停牌，此举旨在推进一项资本筹集计划，为与范德比尔特健康（Vanderbilt Health）合作开展的研究项目提供资金支持。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PER.AU","BK7096"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1151077858","title":"Percheron Therapeutics Ltd——範德比爾特健康中心將開展Hmbd-002治療急性髓系白血病的臨床試驗","url":"https://stock-news.laohu8.com/highlight/detail?id=1151077858","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1151077858?lang=zh_tw&edition=fundamental","pubTime":"2026-08-28 06:12","pubTimestamp":1787868773,"startTime":"0","endTime":"0","summary":"Percheron Therapeutics Ltd宣布，范德比尔特健康中心将主导一项针对Hmbd-002的临床试验，该试验聚焦于急性髓系白血病的治疗。此次与范德比尔特健康中心的携手，有望为急性髓系白血病患者带来新的治疗选择。临床试验的具体细节尚未完全披露，但此举无疑凸显了Percheron Therapeutics在肿瘤学领域的持续深耕。急性髓系白血病是一种进展迅速的血癌，现有治疗方案有限，且复发风险较高。Percheron Therapeutics此番布局，正是瞄准了这一未被满足的医疗需求。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PER.AU","BK7096"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":4,"totalPage":1,"pageCount":1,"totalSize":2,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/market/plate/belongs/PER.AU\",params:#limit:6,delay:true,,,undefined,":[]}}